Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Operating Expenses (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Operating Expenses for 7 consecutive years, with $293.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 26.66% to $293.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 25.85% year-over-year, with the annual reading at $1.0 billion for FY2025, 25.85% up from the prior year.
  • Operating Expenses hit $293.7 million in Q4 2025 for BridgeBio Pharma, up from $265.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $293.7 million in Q4 2025 to a low of $128.0 million in Q1 2023.
  • Historically, Operating Expenses has averaged $184.7 million across 5 years, with a median of $176.5 million in 2022.
  • Biggest five-year swings in Operating Expenses: dropped 27.02% in 2023 and later skyrocketed 64.68% in 2024.
  • Year by year, Operating Expenses stood at $178.5 million in 2021, then dropped by 26.55% to $131.1 million in 2022, then soared by 36.66% to $179.2 million in 2023, then increased by 29.44% to $231.9 million in 2024, then increased by 26.66% to $293.7 million in 2025.
  • Business Quant data shows Operating Expenses for BBIO at $293.7 million in Q4 2025, $265.9 million in Q3 2025, and $244.8 million in Q2 2025.